Q4 2023 13F Holders as of 31 Dec 2023
-
Type / Class
-
Debt / NOTE 1.750% 2/1
-
Market price (% of par)
-
75.94%
-
Total 13F principal
-
$264,943,000
-
Principal change
-
+$19,224,758
-
Total reported market value
-
$201,238,321
-
Number of holders
-
23
-
Value change
-
+$13,097,322
-
Number of buys
-
7
-
Number of sells
-
11
Institutional Holders of REVANCE THERAPEUTICS INC - NOTE 1.750% 2/1 as of Q4 2023
As of 31 Dec 2023,
REVANCE THERAPEUTICS INC - NOTE 1.750% 2/1 was held by
23 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$264,943,000
in principal (par value) of the bond.
The largest 10 bondholders included
FRANKLIN RESOURCES INC, D. E. Shaw & Co., Inc., Graham Capital Management, L.P., UBS OCONNOR LLC, Context Capital Management, LLC, AVIVA PLC, HIGHBRIDGE CAPITAL MANAGEMENT LLC, SILVERBACK ASSET MANAGEMENT LLC, SSI INVESTMENT MANAGEMENT LLC, and Calamos Advisors LLC.
This page lists
23
institutional bondholders reporting positions
for the Q4 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.